Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

Analysts polled by FactSet expected Regeneron Pharmaceuticals REGN to earn $9.65 a share and report $3.59 billion in sales.

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Avon, then known as California Perfume Co., moved its laboratory and manufacturing to Suffern in 1897. The cosmetics behemoth ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...

Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you ...

Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to soaring demand for its anti-inflammatory drug.

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...